Trials / Completed
CompletedNCT03509922
A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity
A Randomized, Dose-controlled, Open-label, Parallel, 2-treatment Group, Single Center, Pilot Study to Evaluate the Effectiveness of Sarpogrelate on Blood Hyperviscosity in the Patients With Peripheral Arterial Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the effect of sarpogrelate on blood viscosity after 24 weeks in patients with high blood viscosity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anplag Tab. 100mg bid | sarpogrelate hydrochloride 100mg bid for 24 weeks |
| DRUG | Anplag Tab. 100mg tid | sarpogrelate hydrochloride 100mg tid for 24 weeks |
Timeline
- Start date
- 2018-10-11
- Primary completion
- 2019-12-26
- Completion
- 2020-03-05
- First posted
- 2018-04-26
- Last updated
- 2020-06-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03509922. Inclusion in this directory is not an endorsement.